دورية أكاديمية
أعرض في EDS

Application of PD-1 Blockade in Cancer Immunotherapy.

التفاصيل البيبلوغرافية
العنوان: Application of PD-1 Blockade in Cancer Immunotherapy.
المؤلفون: Wu X; Dermatology Institute of Fuzhou, Dermatology Hospital of Fuzhou, Xihong Road 243, Fuzhou 350025, PR China.; Department of Biomedicine, University of Basel, Klingelbergstr. 70, CH-4056 Basel, Switzerland., Gu Z; The Institute of Biomedical Sciences, Fudan University, Mingdao Building, Dongan Road 131, Shanghai 200032, PR China., Chen Y; Dermatology Institute of Fuzhou, Dermatology Hospital of Fuzhou, Xihong Road 243, Fuzhou 350025, PR China., Chen B; Dermatology Institute of Fuzhou, Dermatology Hospital of Fuzhou, Xihong Road 243, Fuzhou 350025, PR China., Chen W; Liver Disease Center, The First Affiliated Hospital of Fujian Medical University, Chazhong Road 20, Fuzhou 350005, PR China., Weng L; Dermatology Institute of Fuzhou, Dermatology Hospital of Fuzhou, Xihong Road 243, Fuzhou 350025, PR China., Liu X; The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Xihong Road 312, Fuzhou 350025, PR China.
المصدر: Computational and structural biotechnology journal [Comput Struct Biotechnol J] 2019 May 23; Vol. 17, pp. 661-674. Date of Electronic Publication: 2019 May 23 (Print Publication: 2019).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology Country of Publication: Netherlands NLM ID: 101585369 Publication Model: eCollection Cited Medium: Print ISSN: 2001-0370 (Print) Linking ISSN: 20010370 NLM ISO Abbreviation: Comput Struct Biotechnol J Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: Amsterdam : Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology
Original Publication: Gothenburg, Sweden : Research Network of Computational and Structural Biotechnology
مستخلص: The programmed cell death protein 1 (PD-1) pathway has received considerable attention due to its role in eliciting the immune checkpoint response of T cells, resulting in tumor cells capable of evading immune surveillance and being highly refractory to conventional chemotherapy. Application of anti-PD-1/PD-L1 antibodies as checkpoint inhibitors is rapidly becoming a promising therapeutic approach in treating tumors, and some of them have successfully been commercialized in the past few years. However, not all patients show complete responses and adverse events have been noted, suggesting a better understanding of PD-1 pathway mediated immunosuppression is needed to predict patient response and improve treatment efficacy. Here, we review the progresses on the studies of the mechanistic role of PD-1 pathway in the tumor immune evasion, recent clinical development and commercialization of PD-1 pathway inhibitors, the toxicities associated with PD-1 blockade observed in clinical trials as well as how to improve therapeutic efficacy and safety of cancer immunotherapy.
References: Exp Hematol. 1996 Sep;24(11):1275-9. (PMID: 8862437)
Br J Cancer. 2018 Jan;118(1):9-16. (PMID: 29319049)
J Proteomics. 2019 Jan 16;191:68-79. (PMID: 29621648)
Cell. 2017 Feb 9;168(4):707-723. (PMID: 28187290)
Science. 2001 Jan 12;291(5502):319-22. (PMID: 11209085)
N Engl J Med. 2017 Nov 16;377(20):1919-1929. (PMID: 28885881)
Nature. 2007 Mar 8;446(7132):153-8. (PMID: 17344846)
N Engl J Med. 2016 Nov 10;375(19):1856-1867. (PMID: 27718784)
Nat Rev Immunol. 2018 Mar;18(3):168-182. (PMID: 29226910)
N Engl J Med. 2015 Nov 5;373(19):1803-13. (PMID: 26406148)
Leuk Lymphoma. 2010 Jul;51(7):1293-304. (PMID: 20377308)
Int Immunol. 2007 Jul;19(7):813-24. (PMID: 17606980)
Cancer Res. 2016 Jan 15;76(2):275-82. (PMID: 26567139)
Clin Dev Immunol. 2012;2012:656340. (PMID: 22611421)
Science. 2015 Apr 3;348(6230):124-8. (PMID: 25765070)
Lancet Oncol. 2016 Sep;17(9):1283-94. (PMID: 27451390)
Br Med J. 1957 Apr 6;1(5022):779-86. (PMID: 13404306)
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11695-700. (PMID: 16864790)
Cancers (Basel). 2014 Aug 13;6(3):1670-90. (PMID: 25125485)
Lancet. 2016 May 7;387(10031):1909-20. (PMID: 26952546)
Cancer Res. 2004 Feb 1;64(3):1140-5. (PMID: 14871849)
Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11823-8. (PMID: 16087865)
J Clin Oncol. 2016 Sep 10;34(26):3119-25. (PMID: 27269937)
Lancet. 2016 Apr 9;387(10027):1540-1550. (PMID: 26712084)
Yonsei Med J. 2017 Sep;58(5):1031-1039. (PMID: 28792150)
Lancet. 2017 Jun 24;389(10088):2492-2502. (PMID: 28434648)
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7769-E7777. (PMID: 27837027)
Cancer Immunol Res. 2015 Jun;3(6):602-9. (PMID: 25795007)
N Engl J Med. 2010 Aug 19;363(8):711-23. (PMID: 20525992)
Science. 2018 Mar 23;359(6382):1366-1370. (PMID: 29567708)
Lancet Oncol. 2015 Apr;16(4):375-84. (PMID: 25795410)
Lancet Oncol. 2017 Mar;18(3):312-322. (PMID: 28131785)
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7. (PMID: 12218188)
JAMA Oncol. 2016 Oct 01;2(10):1346-1353. (PMID: 27367787)
Lancet. 2017 Oct 21;390(10105):1853-1862. (PMID: 28822576)
N Engl J Med. 2015 Jun 25;372(26):2509-20. (PMID: 26028255)
J Clin Oncol. 2016 Jun 20;34(18):2141-7. (PMID: 27022117)
Cancer Immunol Immunother. 2018 Mar;67(3):367-379. (PMID: 29124314)
J Immunol. 2004 Oct 15;173(8):4919-28. (PMID: 15470033)
J Immunother Cancer. 2018 Jan 23;6(1):8. (PMID: 29357948)
Cancer Immunol Res. 2016 Oct;4(10):820-822. (PMID: 27538576)
Ann Surg. 1891 Sep;14(3):199-220. (PMID: 17859590)
Lancet. 2014 Sep 20;384(9948):1109-17. (PMID: 25034862)
N Engl J Med. 2015 Nov 12;373(20):1979. (PMID: 26559583)
Science. 2013 Mar 29;339(6127):1546-58. (PMID: 23539594)
Immunol Rev. 2008 Aug;224:11-43. (PMID: 18759918)
N Engl J Med. 2012 Jun 28;366(26):2443-54. (PMID: 22658127)
Immunity. 2016 Oct 18;45(4):931-943. (PMID: 27717798)
EMBO J. 1992 Nov;11(11):3887-95. (PMID: 1396582)
Hum Immunol. 2008 Nov;69(11):790-6. (PMID: 18817829)
J Exp Med. 2000 Oct 2;192(7):1027-34. (PMID: 11015443)
Immunity. 1999 Aug;11(2):141-51. (PMID: 10485649)
Arch Immunol Ther Exp (Warsz). 2018 Apr;66(2):113-123. (PMID: 29032490)
Genome Med. 2017 Apr 19;9(1):34. (PMID: 28420421)
Trends Immunol. 2018 Mar;39(3):173-184. (PMID: 29336991)
N Engl J Med. 2017 Nov 9;377(19):1824-1835. (PMID: 28891423)
Nat Med. 2003 Dec;9(12):1477-83. (PMID: 14595408)
N Engl J Med. 2016 Nov 10;375(19):1823-1833. (PMID: 27718847)
J Immunother. 2016 May;39(4):171-80. (PMID: 27070448)
Lancet Oncol. 2016 Oct;17(10):1374-1385. (PMID: 27592805)
Lancet Oncol. 2017 Nov;18(11):1483-1492. (PMID: 28967485)
Cancer Immunol Res. 2016 Nov;4(11):959-967. (PMID: 27671167)
Nat Med. 2003 May;9(5):562-7. (PMID: 12704383)
Ann N Y Acad Sci. 2011 Jan;1217:45-59. (PMID: 21276005)
Immunol Today. 1997 Jun;18(6):286-91. (PMID: 9190115)
Lancet. 2017 Jan 21;389(10066):255-265. (PMID: 27979383)
Nat Rev Immunol. 2008 Jun;8(6):467-77. (PMID: 18500231)
Eur J Immunol. 1998 Jan;28(1):122-33. (PMID: 9485192)
Cell. 2008 May 30;133(5):775-87. (PMID: 18510923)
Annu Rev Immunol. 2001;19:565-94. (PMID: 11244047)
J Urol. 2018 Feb;199(2):341-342. (PMID: 29357560)
N Engl J Med. 2018 Apr 05;378(14):1277-1290. (PMID: 29562145)
Nature. 2014 Nov 27;515(7528):563-7. (PMID: 25428504)
Oncotarget. 2016 Oct 25;7(43):69188-69199. (PMID: 27596625)
Oncologist. 2017 Apr;22(4):470-479. (PMID: 28275115)
J Cell Physiol. 2018 Apr;233(4):3024-3036. (PMID: 28661031)
N Engl J Med. 2015 Oct 22;373(17):1627-39. (PMID: 26412456)
N Engl J Med. 2015 May 21;372(21):2006-17. (PMID: 25891304)
J Clin Oncol. 2017 Jul 1;35(19):2125-2132. (PMID: 28441111)
Nature. 2015 Nov 12;527(7577):249-53. (PMID: 26503055)
Eur J Immunol. 1997 Aug;27(8):1994-2000. (PMID: 9295037)
Nature. 2018 Jan 18;553(7688):347-350. (PMID: 29320474)
N Engl J Med. 2016 Jun 30;374(26):2542-52. (PMID: 27093365)
PLoS One. 2017 Apr 28;12(4):e0176822. (PMID: 28453554)
Lancet Oncol. 2016 Jul;17(7):956-965. (PMID: 27247226)
Nat Med. 2002 Aug;8(8):793-800. (PMID: 12091876)
Lancet. 2016 Apr 30;387(10030):1837-46. (PMID: 26970723)
Lancet Oncol. 2016 Nov;17(11):1497-1508. (PMID: 27745820)
N Engl J Med. 2015 Sep 24;373(13):1270-1. (PMID: 26398076)
Immunol Rev. 2010 Jul;236:219-42. (PMID: 20636820)
N Engl J Med. 2015 Jul 2;373(1):23-34. (PMID: 26027431)
J Thorac Dis. 2018 Apr;10(Suppl 9):S1032-S1036. (PMID: 29850182)
Cancer Cell. 2018 Apr 9;33(4):581-598. (PMID: 29634946)
BMC Med. 2016 Oct 25;14(1):168. (PMID: 27776519)
Nature. 2011 Dec 21;480(7378):480-9. (PMID: 22193102)
Science. 2013 Nov 22;342(6161):971-6. (PMID: 24264990)
Cell Death Dis. 2015 Jul 02;6:e1802. (PMID: 26136075)
N Engl J Med. 2018 May 31;378(22):2078-2092. (PMID: 29658856)
Lancet. 2017 Jan 7;389(10064):67-76. (PMID: 27939400)
N Engl J Med. 2015 Nov 12;373(20):1979. (PMID: 26559582)
Autoimmun Rev. 2013 Sep;12(11):1091-100. (PMID: 23792703)
Blood Rev. 2018 Nov;32(6):480-489. (PMID: 29709247)
N Engl J Med. 2017 Mar 16;376(11):1015-1026. (PMID: 28212060)
Lancet Oncol. 2017 Sep;18(9):1182-1191. (PMID: 28734759)
Science. 2018 Jan 5;359(6371):91-97. (PMID: 29097494)
Nat Med. 1999 Dec;5(12):1365-9. (PMID: 10581077)
J Biomed Sci. 2017 Apr 4;24(1):26. (PMID: 28376884)
Nature. 2017 Jan 18;541(7637):321-330. (PMID: 28102259)
J Natl Cancer Inst. 2015 Mar 05;107(3):. (PMID: 25745014)
Nat Med. 2015 Oct;21(10):1122-3. (PMID: 26444633)
Immunol Cell Biol. 2003 Apr;81(2):106-13. (PMID: 12631233)
J Exp Med. 2009 Aug 3;206(8):1717-25. (PMID: 19581407)
N Engl J Med. 2015 Jul 9;373(2):123-35. (PMID: 26028407)
N Engl J Med. 2015 Jun 25;372(26):2521-32. (PMID: 25891173)
J Immunol. 1997 Sep 1;159(5):2342-9. (PMID: 9278324)
J Clin Oncol. 2017 Jul 1;35(19):2117-2124. (PMID: 28375787)
Science. 2018 Mar 23;359(6382):1350-1355. (PMID: 29567705)
Nat Immunol. 2001 Mar;2(3):261-8. (PMID: 11224527)
J Exp Med. 2010 Sep 27;207(10):2187-94. (PMID: 20819927)
Hepatol Res. 2014 Oct;44(10):E318-9. (PMID: 25257690)
Pharmacol Ther. 2019 Feb;194:84-106. (PMID: 30268773)
Cancer Treat Rev. 2017 Jan;52:71-81. (PMID: 27951441)
Sci Transl Med. 2016 Mar 2;8(328):328rv4. (PMID: 26936508)
JAMA Oncol. 2018 May 10;4(5):e180013. (PMID: 29543932)
Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S8-S20. (PMID: 29299404)
Nat Rev Immunol. 2018 Mar;18(3):153-167. (PMID: 28990585)
Science. 2017 Jul 28;357(6349):409-413. (PMID: 28596308)
N Engl J Med. 2015 Jan 22;372(4):311-9. (PMID: 25482239)
Science. 2013 Nov 22;342(6161):967-70. (PMID: 24264989)
Science. 2015 Apr 3;348(6230):56-61. (PMID: 25838373)
Eur J Immunol. 2017 Aug;47(8):1256-1265. (PMID: 28631311)
Science. 1996 Mar 22;271(5256):1734-6. (PMID: 8596936)
Nat Rev Drug Discov. 2019 Mar;18(3):175-196. (PMID: 30622344)
Drug Des Devel Ther. 2018 Jul 06;12:2085-2096. (PMID: 30013326)
فهرسة مساهمة: Keywords: 5-AZA-dC, 5-aza-2′-deoxycytidine; ADCC, Antibody-dependent cellular cytotoxicity; AEs, Adverse events; AP1, Activator protein 1; APCs, Antigen presenting cells; ASCT, Autologous stem cell transplantation; B2M, β2 microglobulin; BATF, Basic leucine zipper transcriptional factor ATF-like; BICR, Blinded Independent Central Review; BV, Brentuximab vedotin; CC, Cervical cancer; CRC, Colorectal cancer; CTLA-4, Cytotoxic T-lymphocyte–associated antigen 4; CXCL9, C-X-C motif chemokine ligand 9; Checkpoint blockade; DCM, Dilated cardiomyopathy; DCs, Dendritic cells; DNMT, DNA methyltransferase; DOR, Duration overall response; DZNep, 3-Deazaneplanocin A; ERK, Extracellular signal–regulated kinase; EZH2, Enhancer of zeste homolog 2; GC, Gastric cancer; GEJ, GASTRIC or gastroesophageal junction; HCC, Hepatocellular carcinoma; HNSCC, Head and neck squamous cell carcinoma; HR, Hazard ratio; ICC, Investigator-choice chemotherapy; ICOS, Inducible T-cell co-stimulator; IFN, Interferon; IHC, Immunohistochemistry; ITIM, Immune-receptortyrosine-based inhibitory motif; ITSM, Immune-receptortyrosine-based switch motif; ITT, Intention-to-treat; Immune surveillance; Immunotherapy; IrAEs, Immune related adverse events; JMJD3, Jumonji Domain-Containing Protein 3; LAG3, Lymphocyte-activation gene 3; LCK, Tyrosine-protein kinase Lck; MAP, Mitogen-activated protein; MCC, Merkel cell carcinoma; MHC, Major histocompatibility; MSI-H, Microsatellite instability-high; NF-κB, Nuclear factor-κB; NFAT, Nuclear factor of activated T cells; NSCLC, Non-small cell lung cancer; ORR, Overall response rate; OS, Overall survival; PD-1; PD-1, Programmed cell death 1; PD-L1; PD-L1, Programmed death-ligand 1; PFS, Progression-free survival; PI3K, Phosphoinositide 3-kinase; PKC, Protein kinase C; PMBCL, Primary mediastinal large B-cell lymphoma; PRC2, Polycomb repressive complex 2; PTEN, Phosphatase and tensin homolog; PTPs, Protein tyrosine phosphatases; RCC, Renal cell carcinoma; SCLC, Small cell lung cancer; SHP2, Src homology 2 domain-containing phosphatase 2; SIRPα, Signal-regulatory protein alpha; TCR, T-cell receptor; TGF, Transforming growth factor; TIICs, Tumor infiltrating immune cells; TILs, Tumor-infiltrating lymphocytes; TIM3, T-cell immunoglobulin and mucin-domain containing-3; TMB, Tumor mutation burden; TME, Tumor microenvironment; UC, Urothelial carcinoma; VEGF, Vascular endothelial growth factor; ZAP70, Zeta-chain-associated protein kinase 70; cHL, Classical Hodgkin lymphoma; cTnI, Cardiac troponin I; dMMR, DNA mismatch repair deficiency
تواريخ الأحداث: Date Created: 20190618 Latest Revision: 20240723
رمز التحديث: 20240723
مُعرف محوري في PubMed: PMC6558092
DOI: 10.1016/j.csbj.2019.03.006
PMID: 31205619
قاعدة البيانات: MEDLINE
الوصف
تدمد:2001-0370
DOI:10.1016/j.csbj.2019.03.006